AstraZeneca · 14 hours ago
Senior Scientist – Oncology Targeted Discovery (Drug Conjugates)
US - Waltham - MA
Full-time
Hybrid
Mid, Senior Level
$108K/yr - $163K/yr
3+ years expAstraZeneca is a global biopharmaceutical company focused on transforming patient outcomes through innovative medicines. The Senior Scientist in Oncology Targeted Discovery will bridge advanced computation and wet-lab validation to discover novel targets and deliver predictive biomarkers, directly influencing cancer treatment strategies.
BiopharmaBiotechnologyHealth CareMedicalPharmaceuticalPrecision Medicine
Responsibilities
Bioinformatics Discovery: Mine and integrate diverse datasets (public, consortium, proprietary clinical) to identify novel targets, predictive biomarkers, rational combinations, and optimized dosing strategies
Multi-omics Sample Generation: Oversee high-quality sample generation for RNASeq, scRNASeq, ATACSeq, proteomics, and phospho-proteomics to ensure reliable downstream analysis
Cancer Signaling Interpretation: Apply deep knowledge of cancer signaling pathways to interpret proteomic and transcriptomic changes that reveal mechanisms and vulnerabilities
Single-Cell Analytics: Analyze and interpret high-dimensional scRNASeq data to uncover cellular heterogeneity and generate tractable biological hypotheses
Spatial and Transcriptomic Study Leadership: Design and analyze single-cell and spatial transcriptomic studies to map the molecular landscape of the tumor microenvironment
AI/ML for Mechanism of Action: Utilize AI/ML tools to elucidate mechanisms of action for therapeutics, with emphasis on antibody-drug conjugates
Target Identification and Strategy: Identify clinically relevant, tractable targets across hematologic and solid tumors and propose comprehensive intervention strategies
Biomarker Development: Develop robust molecular signatures and biomarkers predictive of response versus resistance to optimize patient stratification across tumor types
Clinical Reverse Translation: Reverse translate key clinical findings to inform and refine predictive in vitro preclinical models in both heme and solid tumors
Translational Integration: Translate bioinformatics-derived findings into laboratory experiments to progress projects, propose new targets, and support go/no-go decision-making
Data Package Delivery: Deliver high-quality data packages that define mechanism of action and therapeutic efficacy and inform portfolio strategy
Microscopy Validation: Use advanced microscopy, including fluorescence-based live-cell imaging and immunofluorescence staining, to validate computational predictions
Qualification
Required
Candidate must hold a minimum of 1 year proven experience with a postdoctoral degree, or a minimum of 3 years industry experience with a master's degree
Sophisticated bioinformatics analysis and data mining across public datasets (e.g., TCGA, CCLE), large consortium datasets, and proprietary clinical data to identify targets, biomarkers, combination partners, and dosing regimens
Oversight of high-quality sample generation for multi-omics pipelines including RNASeq, scRNASeq, ATACSeq, proteomics, and phospho-proteomics
Expertise in cancer cell signaling pathways to interpret proteomic and transcriptomic changes
Proven ability to analyze and interpret high-dimensional single-cell RNASeq to uncover heterogeneity and produce actionable hypotheses
Experience leading design and analysis of transcriptomic studies, including single-cell and spatial approaches, to map the tumor microenvironment
Utilization of AI/ML tools to elucidate mechanism of action for therapeutics, specifically ADCs
Identification of clinically relevant, tractable drug targets in hematologic and solid tumors and development of comprehensive intervention strategies
Development of robust molecular signatures and biomarkers predictive of performance versus resistance to optimize patient stratification in heme and solid tumors
Reverse translation of key clinical findings to inform predictive in vitro preclinical model development in heme and solid tumors
Translation of bioinformatics findings into laboratory experiments to advance project goals, propose new targets, and inform go/no-go decisions
Delivery of high-quality data packages that define mechanism of action and therapeutic efficacy in heme and solid tumors
Advanced microscopy skills, including fluorescence-based live-cell imaging and immunofluorescence staining, to validate computational predictions
Preferred
Ph.D. in Bioinformatics, Computational Biology, Cancer Biology, or a related field
Practical experience with ADC target selection criteria, linker/payload considerations, and resistance mechanisms
Proficiency in R and/or Python, workflow management (e.g., Snakemake, Nextflow), version control, and scalable/cloud computing for multi-omic analytics
Experience with spatial transcriptomics technologies and image analysis workflows that integrate with single-cell data
Familiarity with building predictive biomarker models and patient stratification algorithms and validating them in preclinical systems
Strong cross-functional communication, scientific storytelling, and the ability to influence decision-making with clear data narratives
Prior leadership in cross-disciplinary studies that connect computation, assay development, and disease biology to deliver decision-grade data
Benefits
Qualified retirement programs
Paid time off (i.e., vacation, holiday, and leaves)
Health, dental, and vision coverage
Company
AstraZeneca
AstraZeneca is a pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines. It is a sub-organization of Investor.
10001+ employees
H1B Sponsorship
AstraZeneca has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2021 (2)
2020 (11)
Funding
Current Stage
Public CompanyTotal Funding
$5.26B2024-07-30Post Ipo Debt· $1.51B
2023-02-28Post Ipo Debt· $2.25B
2023-02-24Post Ipo Debt· $1.5B
Leadership Team
Pascal Soriot
Executive Director and Chief Executive Officer
Aradhana Sarin
Group CFO and Executive Director
Recent News
Essential Business
2026-01-24
2026-01-23
Company data provided by crunchbase